A cancer risk assessment of di(2-ethylhexyl)phthalate: Application of the new U.S. EPA risk assessment guidelines

Regulatory Toxicology and Pharmacology

Volumn 29, Issue 3, 1999, Pages 327-357

  Doull, John ^a   Cattley, Russell ^b   Elcombe, Cliff ^c   Lake, Brian G ^d   Swenberg, James ^e   Wilkinson, Christopher ^f   Williams, Gary ^g   Van Gemert, Marcia ^h,i  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b CIIT CENTERS FOR HEALTH RESEARCH   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

^d BIBRA International   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f Schwartz Connolly Inc   (United States)

^g AMERICAN HEALTH FOUNDATION   (United States)

^h LLC   (United States)

ⁱ NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLHEXANOL; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BECLOBRINIC ACID; BENZBROMARONE; BEZAFIBRATE; CIPROFIBRATE; CLOFIBRATE; CLOFIBRIC ACID; FENOFIBRATE; FENOFIBRIC ACID; FOMESAFEN; GEMFIBROZIL; METHYLCLOFENAPATE; NAFENOPIN; OXADIAZON; PEROXISOME PROLIFERATOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PIRINIXIC ACID; PRASTERONE; TOMELUKAST; TRICHLOROACETIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER RISK; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; ENVIRONMENTAL PROTECTION; FOOD CONTAMINATION; GENOTOXICITY; HEMODIALYSIS; HUMAN; KUPFFER CELL; LIVER CANCER; MATHEMATICAL ANALYSIS; MITOGENESIS; NONHUMAN; OCCUPATIONAL EXPOSURE; OXIDATIVE STRESS; PEROXISOME; PRIORITY JOURNAL; RISK ASSESSMENT; SPECIES DIFFERENCE; TOXICOLOGY;

EID: 0033001883     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1999.1296     Document Type: Article

References (179)

1. Albro, P. W., and Levenhar, S. R. (1989). Metabolism of di(2-ethylhexyl)phthalate. Drug Metab. Rev. 21(1), 13-34.
2. Albro, P. W. (1986). Absorption, metabolism and excretion of di(2-ethylhexyl) phthalate by rats and mice. Environ. Health Perspect. 65, 293-298.
3. Albro, P. W., Hass, J. R., Peck, C. C., et al. (1979). Identification of the metabolites of di(2-ethylhexyl)phthalate in urine from the African green monkey. Drug Metab. Dispos. 9(3), 223-225.
4. Albro, P. W., Thomas, R., and Fishbein, L. (1973). Metabolism of di-ethylhexylphthalate by rats. Isolation and characterization of the urinary metabolites. J. Chromatogr. 76, 321-330.
5. Albro, P. W., Corbett, J. T., Schroeder, J. L., Jordan, S., and Matthews, H. B. (1982). Pharmacokinetics, interactions with macromolecules and species differences in metabolism of DEHP. Environ. Health Perspect. 45, 19-25.
6. Allen, K. L., Green, C. E., and Tyson, C. A. (1987). Comparative studies on peroxisomal enzyme induction in hepatocytes from rat, Cynomolgus monkey and human by hypolipidemic drugs. Toxicologist 7, Abstract No. 253.
7. Ashby, J., de Serres, F. J., Draper, M., et al. (1985). Evaluation of Short-Term Tests for Carcinogen, pp. 1-752. Elsevier Science Publishers, Amsterdam.
8. Ashby, J., Brady, A., Elcombe, C. R., et al. (1994). Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Hum. Exp. Toxicol. 13(Suppl. 2), S1-S117.
9. Auboeuf, D., Rieusset, J., Fajas, L., Vallier, P., Frering, V., Riou, J., Staels, B., Auwerx, J., Laville, M., and Vidal, H. (1997). Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-a in humans. Diabetes 46, 1319-1327.
10. Bell, A. R., Savory, R., Horely, N. J., Choudhury, A. I., Dickins, M., Gray, T. J. B., Salter, A. M., and Bell, D. R. (1998). Molecular basis of non-responsiveness to peroxisome proliferators: The guinea pig PPARa is functional and mediates peroxisome proliferator-induced hypolipidaemia. Biochem. J. 332, 689-693.
11. Benford, D. J., Patel, S., Reavy, H. J., Mitchell, A., and Sarginson, N. J. (1986). Species differences in the response of cultured hepatocytes to phthalate esters. Food Chem. Toxicol. 24, 799-800.
12. Bentley, P., Calder, I., Elcombe, C., Grasso, P., Stringer, D., and Wiegand, H.-J. (1993). Hepatic peroxisome proliferation in rodents and its significance for humans. Food Chem. Toxicol. 31, 857-907.
13. Bichet, N., Cahard, D., Fabre, G., Remandet, B., Gouy, D., and Cano, J.-P. (1990). Toxicological studies on a benzofuran derivative. III. Comparison of peroxisome proliferation in rat and human hepatocytes in primary culture. Toxicol. Appl. Pharmacol. 106, 509-517.
14. Bieri, F. (1993). Cultured hepatocytes: A useful in vitro system to investigate effects induced by peroxisome proliferators and their species specificity. In Peroxisomes: Biology and Importance in Toxicology and Medicine (G. Gibson and B. Lake, Eds.), pp. 299-311. Taylor and Francis, London.
15. Bieri, F., Muakkassah-Kelly, S., Waechter, F., Sagelsdorff, P., Staübli, W., and Bentley, P. (1990). The significance of in vitro studies on peroxisome proliferation. Toxicol. In Vitro 4, 428-431.
16. Bieri, F., Bentley, P., Waechter, F., and Stäubli, W. (1984). Use of primary cultures of adult rat hepatocytes to investigate mechanisms of action of nafenopin, a hepatocarcinogenic peroxisome proliferator. Carcinogenesis 5, 1033-1039.
17. Bieri, F., Stäubli, W., Waechter, F., Muakkassah-Kelly, S., and Bentley, P. (1988). Stimulation of DNA synthesis but not of peroxisomal b-oxidation by nafenopin in primary cultures of marmoset hepatocytes. Cell Biol. Int. Rep. 12, 1077-1087.
18. Blaauboer, B. J., van Holsteijn, C. W. M., Bleumink, R., Mennes, W. C., van Pelt, F. N. A. M., Yap, S. H., van Pelt, J. F., van Iersel, A. A. J., Timmerman, A., and Schmid, B. P. (1990). The effect of beclobric acid and clofibric acid on peroxisomal b-oxidation and peroxisome proliferation in primary cultures of rat, monkey and human hepatocytes. Biochem. Pharmacol. 40, 521-528.
19. Blane, G. F., and Pinaroli, F. (1980). Fenofibrate: Études de toxicologie animal en rapport avec les effets secondaires chez les malades. Presse Med. 9, 3737-3746.
20. Blümcke, S., Schwartzkopff, W., Lobeck, H., et al. (1983). Influence of fenofibrate on cellular and subcellular liver structure in hyperlipidemic patients. Atherosclerosis 46, 105-116.
21. Bojes, H. K., and Thurman, R. G. (1996). Peroxisome proliferators activate Kupffer cells in vivo. Cancer Res. 56, 1-4.
22. Bouis, P., Bieri, F., Lang, B., Thomas, H., and Waechter, F. (1993). Effect of propaquizafop and its free-acid derivative on lauric acid hydroxylation and peroxisomal b-oxidation in primary cultured rat, mouse, guinea pig and marmoset hepatocytes. Toxicol. In Vitro 7, 427-431.
23. Braissant, O., Foufelle, F., Scotto, C., Dauca, M., and Wahli, W. (1996). Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPARa, -b, and -w in the adult rat. Endocrinology 137, 354-366.
24. Budroe, J. D., Umemura, T., Angeloff, K., and Williams, G. M. (1992). Dose-response relationships of hepatic acyl-CoA oxidase and catalase activity and liver mitogenesis induced by the peroxisome proliferator ciprofibrate in C57BL/6N and BALB/c mice. Toxicol. Appl. Pharmacol. 113, 192-198.
25. Budroe, J. D., and Williams, G. M. (1993). Genotoxicity studies of peroxisome proliferators. In Peroxisome: Biology and Importance in Toxicology and Medicine (G. G. Gibson and B. G. Lake, Eds.), pp. 525-568. Taylor and Francis, London.
26. Butler, E. G., England, P. J., and Williams, G. M. (1988). Genetic differences in enzymes associated with peroxisome proliferation and hydrogen peroxide metabolism in inbred mouse strains. Carcinogenesis 9, 1459-1463.
27. Butterworth, B. E., Smith-Oliver, T., Earle, L., Loury, D. J., White, R. D., Doolittle, D. J., Working, P. K., Cattley, R. C., Jirtle, R., Michalopoulos, G., and Strom, S. (1989). Use of primary cultures of human hepatocytes in toxicology studies. Cancer Res. 49, 1075-1084.
28. Carpenter, C. P., Weil, C. S., and Smith, H. F., Jr. (1953). Chronic oral toxicity of di(2-ethylhexyl)phthalate for rats, guinea pigs and dogs. Am. Med. Assoc. Arch. Ind. Hyg. Occup. Med. 8, 219-226.
29. Cattley, R. C., Conway, J. G., and Popp, J. A. (1987). Association of persistent peroxisome proliferation and oxidative injury with hepatocarcinogenicity in female F-344 rats fed di(2-ethylhexyl)-phthalate for two years. Cancer Lett. 38, 15-22.
30. Cattley, R. C., and Glover, S. E. (1993). Elevated 8-hydroxydeoxyguanosine in hepatic DNA of rats following exposure to peroxisome proliferators: Relationship to carcinogenesis and nuclear localization. Carcinogenesis 14(12), 2495-2499.
31. Cattley, R., DeLuca, J., Elcombe, C., Fenner-Crisp, P., Lake, B., Marsman, D., Pastoor, T., Popp, J. A., Robinsoh, D. E., Schwetz, B., Tugwood, J., and Wahli, W. (1998). Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul. Toxicol. Pharmacol. 27, 47-60.
32. Chu, I., Villeneuve, D. C., Secours, V., et al. (1978). Metabolism and tissue distribution of mono-2-ethylhexyl phthalate in the rat. Drug Metab. Dispos. 6, 146-149.
33. Cornu, M. C., Lhuguenot, J. C., Brady, A. M., Moore, R., and Elcombe, C. R. (1992). Identification of the proximate peroxisome proliferator(s) derived from di(2-ethylhexyl)adipate and species differences in response. Biochem. Pharmacol. 43, 2129-2134.
34. Cornu-Chagnon, M.-C., Dupont, H., and Edgar, A. (1995). Fenofibrate: Metabolism and species differences for peroxisome proliferation in cultured hepatocytes. Fundam. Appl. Toxicol. 26, 63-74.
35. David, R. M., Moore, M. R., Cifone, M. A., Finney, D. C., and Guest, D. (1996). Further investigations of the oncogenicity of di(2-ethylhexyl) phthalate in rats. Fundam. Appl. Toxicol. 30(Suppl.), 204.
36. David, R. M., Moore, M. R., Cifone, M. A., Finney, D. C., and Guest, D. (1997). Correlation of peroxisome proliferation and oncogenicity of di(2-ethylhexyl) phthalate in mice. Fundam. Appl. Toxicol. 36(Suppl.), 173.
37. De La Iglesia, F. A., Lewis, J. E., Buchanan, R. A., et al. (1982). Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis 43, 19-37.
38. Dirven, H. A. A. M., Van Den Broek, P. H. H., Peeters, M. C. E., Peters, J. G. P., Mennes, W. C., Blaauboer, B. J., Noordhoek, J., and Jongeneelen, F. J. (1993). Effects of the peroxisome proliferator mono(2-ethylhexyl)phthalate in primary hepatocyte cultures derived from rat, guinea pig, rabbit and monkey. Relationship between interspecies differences in biotransformation and peroxisome proliferating potencies. Biochem. Pharmacol. 45, 2425-2434.
39. Dybing, E., Mikalsen, S-O., Huttunen, J. K., and Sanner, T. (1995). Peroxisome proliferation genotoxicity and carcinogenicity. In Peroxisome Proliferation and its Role in Carcinogenesis. IARC Technical Report 24, p. 64. Lyon, France.
40. Eacho, P. I., Foxworthy, P. S., Johnson. W. D., Hoover, D. M., and White, S. L. (1986). Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species. Toxicol. Appl. Pharmacol. 83, 430-437.
41. Easterling, R. E., Johnson, E., and Napier, E. A. (1974). Plasma extraction of plasticizers from "medical grade" Polyvinylchloride tubing. Proc. Soc. Exp. Biol. Med. 147, 572-574.
42. Elcombe, C. R. (1985). Species differences in carcinogenicity and peroxisome proliferation due to trichloroethylene: A biochemical human hazard assessment. Arch. Toxicol. Suppl. 8, 6-17.
43. Elcombe, C. R., and Mitchell, A. M. (1986). Peroxisome proliferation due to di(2-ethylhexyl)phthalate (DEHP): Species differences and possible mechanisms. Environ. Health Perspect. 70, 211-219.
44. Elcombe, C. R., and Styles, J. A. (1989). Species differences in peroxisome proliferation. Toxicologist 9, 63.
45. Elcombe, C. R., Bell, D. R., Elias, E., Hasmall, S. C., and Plant, N. J. (1996). Peroxisome proliferators: Species differences in response of primary hepatocyte cultures. Ann. N.Y. Acad. Sci. 804, 628-635.
46. EPA (U.S. Environmental Protection Agency) (1987). Health Effects Assessment for Selected Phthalic Acid Esters. EPA-600/8-88-053. NTIS PB88-178934, Washington, D.C.
47. EPA (U.S. Environmental Protection Agency) (1989). Ambient Water Criteria Document Addendum for Phthalate Esters, Final Draft, PB91-161653. Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH.
48. EPA (U.S. Environmental Protection Agency) (1996). Proposed Guidelines for Carcinogen Risk Assessment. Office of Research and Development, U.S. Environmental Protection Agency. Fed. Reg. 61(79), 17960-18011.
49. Fan, C. Y., Pan, J., Usuda, N., Yeidaudi, A. V., Rao, M. S., and Reddy, J. K. (1998). Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA-oxidase. J. Biol. Chem. 273, 15639-15645.
50. Flaminio, L. M., Bergia, R., De Angelis, L., Ferazza, M., Marinovich, M., Galli, G., and Galli, C. L. (1988). The fate of leached di-(2-ethylhexyl)-phthalate (DEHP) in patients on chronic hemodialysis. Int. J. Artif. Organs 11(6), 428-435.
51. Foxworthy, P. S., White, S. L., Hoover, D. M., and Eacho, P. I. (1990). Effect of ciprofibrate, bezafibrate, and LY 171883 on peroxisomal b-oxidation in cultured rat, dog and Rhesus monkey hepatocytes. Toxicol. Appl. Pharmacol. 104, 386-394.
52. Foxworthy, P. S., and Eacho, P. I. (1994). Cultured hepatocytes for studies of peroxisome proliferation: Methods and applications. J. Pharmacol. Toxicol. Methods 31, 21-30.
53. Frick, H., Elo, O., Haapa, K., et al. (1987). Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle aged men with dyslipidemia, safety of treatment, changes in risk factors and incidence of coronary heart disease. N. Engl. J. Med. 317, 1235-1247.
54. Furukawa, K., Numoto, S., Furuya, K., Furukawa, N. T., and Williams, G. M. (1985). Effect of hepatocarcinogen nafenopin, a peroxisome proliferator, on the activities of rat liver glutathione-requiring enzymes and catalase in comparison to the action of phenobarbital. Cancer Res. 45, 5011-5019.
55. Canning, A. E. (1987). Effects of Di(2-ethylhexyl)phthalate on the Structure and Function of the Rat Hepatocyte. Dissertation thesis, Univ. Stockholm, Sweden.
56. Canning, A. E., Brunk, U., and Dallner, G. (1984). Phthalate esters and their effect on the liver. Hepatology 4, 541-547.
57. Canning, A. E., Brunk, U., Edlund, C., et al. (1987). Effects of prolonged administration of phthalate ester on the liver. Environ. Health Perspect. 73, 251-258.
58. Gariot, P., Barrat, E., Drouin, P., Genton, P., et al. (1987). Morphometric study of human hepatic cell modifications induced by fenofibrate. Metabolism 36, 203-210.
59. Garvey, L. K., Swenberg, J. A., Hamm, T. E., Jr., and Popp, J. A. (1987). Di(2-ethylhexyl)phthalate: Lack of initiating activity in the liver of female F-344 rats. Carcinogenesis 8, 285-290.
60. Gibson, T. P., Briggs, W. A., and Boone, B. J. (1976). Delivery of di-2-ethylhexyl phthalate to patients during hemodialysis. J. Lab. Clin. Med. 87(3), 519-524.
61. Goodman, D. G., Ward, J. M., Squire, R. A., and Chu, K. C. (1979). Neoplastic and nonneoplastic lesions in aging F344 rats. Toxicol. Appl. Pharmacol. 48, 237-248.
62. Graham, M. J., Wilson, S. A., Winham, M. A., et al. (1994). Lack of peroxisome proliferation in marmoset liver following treatment with ciprofibrate for 3 years. Fundam. Appl. Toxicol. 22, 58-64.
63. Gray, T. J. B., Lake, B. G., Beamand, J. A., Foster, J. R., and Gangolli, S. D. (1983). Peroxisome proliferation in primary cultures of rat hepatocytes. Toxicol. Appl. Pharmacol. 67, 15-25.
64. Green, S. (1995). PPAR: A mediator of peroxisome proliferator action. Mutat. Res. 333, 101-109.
65. Hanefeld, M., Kemmer, C., Leonhardt, W., et al. (1980). Effects of p-chlorophenoxy-isobutyric acid (CPIB) on the human liver. Atherosclerosis 36, 159-172.
66. Hanefeld, M., Kemper, C., and Kadner, E. (1983). Relationship between morphological changes and lipid-lowering action of p-chlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis 46, 239-246.
67. Harris, R. S., Hodge, H. C., Maynard, E. A., and Blanchet, H. J. J. (1956). Chronic oral toxicity of di(2-ethylhexyl)phthalate in rats and dogs. Arch. Ind. Health 13, 259-264.
68. Holloway, B. R., Thorp, J. M., Smith, G. D., and Peters, T. J. (1982). Analytical subcellular fractionation and enzymatic analysis of liver homogenates from control and clofibrate-treated rats, mice, and monkeys with reference to the fatty acid oxidizing enzymes. Ann. N.Y. Acad. Sci. 386, 453-455.
69. Huber, W. W., Grasl-Kraupp, B., and Schulte-Hermann, R. (1996). Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk. Crit. Rev. Toxicol. 26(4), 365-481.
70. Hsu, M.-H., Palmer, C. A. N., Griffin, K. J., and Johnson, E. F. (1995). A single amino acid change in the mouse peroxisome proliferator-activated receptor a alters transcriptional responses to peroxisome proliferators. Mol. Pharmacol. 48, 559-567.
71. IARC (International Agency for Research in Cancer) (1995). Peroxisome Proliferation and Its Role in Carcinogenesis, IARC Technical Report No. 24, pp. 3-85. World Health Organization, Geneva.
72. IARC (International Agency for Research in Cancer) (1982). Di(2-ethylhexyl)phthalate. In Some Industrial Chemicals and Dye-stuffs, IARC Technical Report No. 29, pp. 269-294.
73. IARC (International Agency for Research in Cancer) (1996). Hypolipidaemic Drugs, Vol. 66, pp. 389-485. Lyon.
74. International Programme on Chemical Safety (IPCS) (1992). Environmental Health Criteria Document No. 131, Diethylhexyl Phthalate. World Health Organization, Geneva.
75. Jacobson, M. S., Kevy, S. V., and Grand, R. J. (1977). Effects of a plasticizer leached from polyvinyl chloride on the subhuman primate: A consequence of chronic transfusion therapy. J. Lab. Clin. Med. 89(5), 1066-1079.
76. Jaeger, R. J., and Rubin, R. J. (1972). Migration of a phthalate ester plasticizer from polyvinyl chloride blood bags into stored human blood and its localization in human tissues. N. Engl. J. Med. 287(22), 1114-1118.
77. James, N. H., and Roberts, R. A. (1994). The peroxisome proliferator class of non-genotoxic hepatocarcinogens synergizes with epidermal growth factor to promote clonal expansion of initiated rat hepatocytes. Carcinogenesis 15, 2687-2694.
78. James, N. H., and Roberts, R. A. (1995). Species differences in the clonal expansion of hepatocytes in response to the coaction of epidermal growth factor and nafenopin, a rodent hepatocarcinogenic peroxisome proliferator. Fundam. Appl. Toxicol. 26, 43-149.
79. James, N. H., and Roberts, R. A. (1996). Specific differences in response to peroxisome proliferators correlate in vitro with induction of DNA synthesis rather than suppression of apoptosis. Carcinogenesis 17, 1623-1632.
80. Jow, L., and Mukherjee, R. (1995). The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPARa and thyroid hormone receptors. J. Biol. Chem. 270, 3836-3840.
81. Juge-Aubry, C. E., Gorla-Bajszczak, A., Pernin, A., Lemberger, T., Wahli, W., Burger, A. G., and Meier, C. A. (1995). Peroxisome proliferator-activated receptor mediates cross talk with thyroid hormone receptor by competition for retinoid X receptor. J. Biol. Chem. 270, 18117-18122.
82. Kraupp-Grasl, B., Huber, W., Taper, H., et al. (1991). Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver foci occurring spontaneously. Cancer Res. 51, 666-671.
83. Kraupp-Grasl, B., Huber, W., Putz, B., et al. (1990). Tumor promotion by the peroxisome proliferator nafenopin involving a specific subtype of altered foci in rat liver. Cancer Res. 50, 3701-3708.
84. Kurata, Y., Kidachi, F., Yokoyama, M., et al. (1998). Subchronic toxicity of di(2-ethylhexyl)phthalate in common marmosets: Lack of hepatic peroxisome proliferation, testicular atrophy, or pancreatic acinar cell hyperplasia. Toxicol. Sci. 42, 49-56.
85. Labow, R. S., Tocchi, M., and Rock, G. (1986). Contamination of platelet storage bags by phthalate esters. J. Toxicol. Environ. Health 19, 591-598.
86. Lake, B. G., and Lewis, D. F. V. (1993). Structure-activity relationships for chemically induced peroxisome proliferation in mammalian liver. In Peroxisomes: Biology and Importance in Toxicology and Medicine (G. Gibson and B. Lake, Eds.), pp. 313-342. Taylor and Francis, London.
87. Lake, B. G., Evans, J. G., Cunningham, M. E., and Price, R. J. (1993a). Comparison of the hepatic effects of nafenopin and WY-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster. Environ. Health Perspect. 101, 241-248.
88. Lake, B. G. (1995a). Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals. Annu. Rev. Pharmacol. Toxicol. 35, 483-507.
89. Lake, B. G. (1995b). Peroxisome proliferation: Current mechanisms relating to non-genotoxic carcinogenesis. Toxicol. Lett. 82/83, 673-681.
90. Lake, B. G., Gangolli, S. D., Grasso, P., and Lloyd, A. G. (1975). Studies on the hepatic effects of orally administered di-(2-ethylhexyl)phthalate in the rat. Toxicol. Appl. Pharmacol. 32, 355-367.
91. Lake, B. G., Gray, T. J. B., Foster, J. R., Stubberfield, C. R., and Gangolli, S. D. (1984). Comparative studies on di(2-ethylhexyl)-phthalate-induced hepatic peroxisome proliferation in the rat and hamster. Toxicol. Appl. Pharmacol. 72, 46-60.
92. Lake, B. G., Gray, T. J. B., and Gangolli, S. D. (1986). Hepatic effects of phthalate esters and related compounds - In vivo and in vitro correlations. Environ. Health Perspect. 67, 283-290.
93. Lake, B. G., Evans, J. G., Gray, T. J. B., et al. (1989). Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset. Toxicol. Appl. Pharmacol. 99, 148-160.
94. Lake, B. G., and Lewis, D. F. V. (1996). The CYP4 family. In Cytochromes P450: Metabolic and Toxicological Aspects (C. Ioannides, Ed.), pp. 271-297. CRC Press, Boca Raton.
95. Lake, B. G., Lewis, D. F. V., Gray, T. J. B., and Beamand, J. A. (1993b). Structure-activity relationships for induction of peroxiso-mal enzyme activities in primary rat hepatocyte cultures. Toxicol. In Vitro 7, 605-614.
96. Lalwani, N. D., Reddy, M. K., Ghosh, S., Barnard, S. D., Molello, J. A., and Reddy, J. K. (1985). Induction of fatty acid b-oxidation and peroxisome proliferation in the liver of Rhesus monkeys by DL-040, a new hypolipidemic agent. Biochem. Pharmacol. 34, 3473-3482.
97. Lapinskas, P. J., and Corton, J. C. (1997). Phthalate ester plasticizers differentially activate the peroxisome proliferator-activated receptors. Fundam. Appl. Toxicol. (Suppl. Toxicologist) 36, 144.
98. Lazarow, P. B., and deDuve, C. (1976). A fatty acyl-CoA oxidizing system in rat liver peroxisomes: Enhancement by clofibrate, a hypolipidemic drug. Proc. Natl. Acad. Sci. USA 73, 2043-2046.
99. Lee, S. S. T., Pineau, T., Drago, J., lee, E. J., Owens, J. W., Kroetz, D. L., et al. (1995). Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15(6), 3012-3022.
100. Lewis, L. M., Flechtner, T. W., Kerkay, J., Pearson, K. H., and Nakamoto, S. (1978). Bis (2-ethylhexyl) phthalate concentrations in the serum of hemodialysis patients. Clin. Chem. 24(5), 741-746.
101. Lhuguenot, J. C., and Cornu, M. C. (1993). Metabolism of di-(2-ethylhexyl)-phthalate (DEHP) and di-(2-ethylhexyl)-adipate (DEHA) and their relationship to peroxisome proliferation in different species. In Peroxisomes: Biology and Importance in Toxicology and Medicine (G. Gibson and B. Lake, Eds.), pp. 465-485. Taylor and Francis, London.
102. Lundgren, B., Meijer, J., and DePierre, J. W. (1987). Examination of the structural requirements for proliferation of peroxisomes and mitochondria in mouse liver by hypolipidemic agents, with special emphasis on structural analogues of 2-ethylhexanoic acid. Eur. J. Biochem. 163, 423-431.
103. Makowska, J. M., Gibson, G. G., and Bonner, F. W. (1992). Species differences in ciprofibrate induction of hepatic cytochrome P450 4A1 and peroxisome proliferation. J. Biochem. Toxicol. 7, 183-191.
104. Mannaerts, G. P., and Van Veldhoven, P. P. (1993). Metabolic role of mammalian peroxisomes. In Peroxisomes: Biology and Importance in Toxicology and Medicine (G. Gibson and B. Lake, Eds.), pp. 19-62. Taylor and Francis, London.
105. Marsman, D. S., and Popp, J. A. (1994). Biological potential of basophilic hepatocellular foci and hepatic adenoma induced by the peroxisome proliferator, WY-14, 643. Carcinogenesis 15(1), 111-117.
106. Marsman, D. S., Cattley, R. C., Conway, J. G., and Popp, J. A. (1988). Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (WY-14,643) in rats. Cancer Res. 48, 6739-6744.
107. Marsman, D. S., Swanson-Pfeiffer, C. L., and Popp, J. A. (1993). Lack of comitogenicity by the peroxisome proliferator hepatocarcinogens, Wy-14,643 and clofibric acid. Toxicol. Appl. Pharmacol. 122, 1-6.
108. Maruyama, H., Tanaka, T., and Williams, G. M. (1990). Effects of the peroxisome proliferator di(2-ethylhexyl)phthalate on enzymes in rat liver and on carcinogen-induced liver altered foci in comparison to the promoter phenobarbital. Toxicol. Pathol. 18(2), 257-267.
109. Mennes, W. C., Wortelboer, H. M., Hassing, G. A. M., van Sandwijk, K., Timmerman, A., Schmid, B. P., Jahn, U., and Blaauboer, B. J. (1994). Effects of clofibric and beclobric acid in rat and monkey hepatocyte primary culture: Influence on peroxisomal and mitochondrial b-oxidation and the activity of catalase, glutathione S-transferase and glutathione peroxidase. Arch. Toxicol. 68, 506-511.
110. Mitchell, F. E., Price, S. C., Hinton, R. H., Grasso, P., and Bridges, J. W. (1985a). Time and dose-response study of the effects on rats of the plasticizer di(2-ethylhexyl)phthalate. Toxicol. Appl. Pharmacol. 81, 371-392.
111. Mitchell, A. M., Lhuguenot, J.-C., Bridges, J. W., and Elcombe, C. R. (1985b). Identification of the proximate peroxisome proliferator(s) derived from di(2-ethylhexyl)phthalate. Toxicol. Appl. Pharmacol. 80, 23-32.
112. Miyamoto, T., Kaneko, A., Kakizawa, T., Yajima, H., Kamijo, K., Sekine, R., Hiramatsu, K., Nishim, Y., Hashimoto, T., and Hashizume, K. (1997). Inhibition of peroxisome proliferator signaling pathways by thyroid hormone receptor. J. Biol. Chem. 272, 7752-7758.
113. Miyata, K. S., McCaw, S. E., Patel, H. V., Rachubinski, R. A., and Capone, J. P. (1996). The orphan nuclear hormone receptor LXRa interacts with the peroxisome proliferator-activated receptor and inhibits peroxisome proliferator signaling. J. Biol. Chem. 271, 9189-9192.
114. Moody, D. E., and Reddy, J. K. (1978). Hepatic peroxisome (microbody) proliferation in rats fed plasticizers and related compounds. Toxicol. Appl. Pharmacol. 45, 497-504.
115. Mukherjee, R., Jow, L., Noonan, D., and McDonnell, D. P. (1994). Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J. Steroid Biochem. Mol. Biol. 51, 157-166.
116. National Toxicology Program (NTP) (1982a). Carcinogenesis bioassay of di-(2-ethylhexyl)phthalate (CAS No. 117-81-7) in F344 rats and B6C3F1 mice (feed study). Tech. Rep. Ser. 217.
117. National Toxicology Program (NTP) (1982b). Carcinogenesis bioassay of di(2-ethylhexyl)adipate (CAS No. 103-23-1) in F344 rats and B6C3F1 mice (feed study). Tech. Rep. Ser. 212.
118. National Toxicology Program (NTP) (1996). Tumor Incidence in Control Animals by Route and Vehicle of Administration - F344 Rats. Contract No. N01-ES-65401, Analytical Sciences, Inc.
119. Orton, T. C., Adam, H. K., Bentley, M., Holloway, B., and Tucker, M. J. (1984). Clobuzarit: Species differences in the morphological and biochemical response of the liver following chronic administration. Toxicol. Appl. Pharmacol. 73, 138-151.
120. Osumi, T., and Hashimoto, T. (1978). Enhancement of fatty acyl-CoA oxidizing activity in rat liver peroxisomes by di(2-ethylhexyl)-phthalate. J. Biochem. 83, 1361-1365.
121. Palmer, C. N. A., Hsu, M.-H., Griffith, K. J., and Johnson, E. F. (1996). Species differences in PPARa expression levels may determine species specific responsiveness to peroxisome proliferators. Abstract, 11th International Symposium on Microsomes and Drug Oxidations, Los Angeles, CA, July 1996.
122. Palmer, C. A. N., Hsu, M.-H., Muerhoff, A. S., Griffin, K. J., and Johnson, E. F. (1994). Interaction of the peroxisome proliferator-activated receptor a with the retenoid X receptor a unmasks a cryptic peroxisome proliferator response element that overlaps an ARP-1-binding site in the CYP4A6 promoter. J. Biol. Chem. 269, 18083-18089.
123. Palmer, C. A. N., Hsu, M.-H., Griffin, K. J., Raucy, J. L., and Johnson, E. F. (1998). Peroxisome proliferator activated receptor-a expression in human liver. Mol. Pharmacol. 53, 14-22.
124. Parzefall, W., Schuppler, J., Barthel, G., et al. (1990). Toxicological studies on a benzofurane derivative. I. A comparative study with phenobarbital on rat liver. Toxicol. Appl. Pharmacol. 106, 482-499.
125. Parzefall, W., Erber, E., Sedivy, R., and Schulte-Hermann, R. (1991). Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat tumor promoters. Cancer Res. 51, 1143-1147.
126. Peck, C. C., Odorn, D. G., Friedman, H. T., et al. (1979). Di-(2-ethylhexyl)phthalate (DEHP) and mono-(2-ethylhexyl)phthalate (MEHP) accumulation in whole blood and red cell concentrates. Transfusion 19, 137-146.
127. Perrone, C. E., Shao, L., and Williams, G. M. (1998). Effect of rodent hepatocarcinogenic peroxisome proliferators on fatty acyl-CoA oxidase, DNA synthesis, and apoptosis in cultured human and rat hepatocytes. Toxicol. Appl. Pharmacol. 150, 277-286.
128. Peters, J. M., Cattley, R. C., and Gonzalez, F. J. (1997). Role of PPARa in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator WY-14,643. Carcinogenesis 18, 2029-2033.
129. Plant, N. J., Horley, N. J., Savory, R. L., Elcombe, C. R., Gray, T. J. B., and Bell, D. R. (1998). The peroxisome proliferators are hepatocyte mitogens in chemically-defined media: Glucocorticoid-induced PPARa is linked to peroxisome proliferator mitogenesis. Carcinogenesis 19, 925-931.
130. Poland, A. (1997). Reflections on risk assessment of receptor-acting xenobiotics. Regul. Toxicol. Pharmacol. 26, 41-43.
131. Pollack, G. M., Li, R. C. K., Ermer, J. C., and Shen, D. D. (1985a). Effects of route of administration and repetitive dosing on the disposition kinetics of di(2-ethylhexyl)phthalate and its mono-di-esterified metabolite in rats. Toxicol. Appl. Pharmacol. 79, 246-256.
132. Pollack, G. M., Buchanan, J. F., Slaughter, R. L., et al. (1985b). Circulating concentration of di(2-ethylhexyl)phthalate and its deesterified phthalic acid products following plasticizer exposure in patients receiving hemodialysis. Toxicol. Appl. Pharmacol. 79, 257-267.
133. Popp, J. A., Garvey, L. K., Hamm, J. T. E., and Swenberg, J. A. (1985). Lack of hepatic promotional activity by the peroxisomal proliferating hepatocarcinogen di(2-ethylhexyl)phthalate. Carcinogenesis 6, 141-144.
134. Popp, J. A., and Cattley, R. C. (1993). Peroxisome proliferators as initiators and promoters of rodent hepatocarcinogenesis. In Peroxisomes: Biology and Importance in Toxicology and Medicine (G. Gibson and B. Lake, Eds.), pp. 653-665. Taylor and Francis, London.
135. Rao, M. S., Lalwani, N. D., Watanabe, T. K., and Reddy, J. K. (1984a). Inhibitory effect of the antioxidants ethoxiquin and 2(3)-tert-butyl-4-hydroxyanisole on hepatic tumorigenesis in rats fed ciprofibrate, a peroxisomal proliferator. Cancer Res. 44, 1072-1076.
136. Rao, M. S., Usuda, N., Subbarao, V., and Reddy, J. K. (1987). Absence of gamma-glutamyl transpeptidase activity in neoplastic lesions induced in the liver of male F-344 rats by di-(2-ethylhexyl)-phthalate, a peroxisome proliferator. Carcinogenesis 8, 1347-1350.
137. Rao, M. S., and Reddy, J. K. (1991). An overview of peroxisome proliferator-induced hepatocarcinogenesis. Environ. Health Perspect. 93, 205-209.
138. Rao, M. S., Yeldandi, A. V., and Subbarao, V. (1990). Quantitative analysis of hepatocellular lesions induced by di(2-ethylhexyl)-phthalate in F-344 rats. J. Toxicol. Environ. Health 30, 85-89.
139. Rao, M. S., Lalwani, N. D., and Reddy, J. K. (1984b). Sequential histologic study of rat liver during peroxisome proliferator (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid (WY-14,643)-induced carcinogenesis. J. Natl. Cancer Inst. 73, 983-990.
140. Reddy, J. K., and Qureshi, S. A. (1979). Tumorigenicity of the hypolipidemic peroxisome proliferator ethyl-a-p-chlorophenoxyisobutyrate (clofibrate) in rats. Br. J. Cancer 40, 476-482.
141. Reddy, J. K., and Mannaerts, G. P. (1994). Peroxisomal lipid metabolism. Annu. Rev. Nutr. 14, 343-370.
142. Reddy, J. K., and Reddy, M. S. (1977). Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator. J. Natl. Cancer Inst. 59, 1645-1650.
143. Reddy, J. K., and Lalwani, N. D. (1983). Carcinogenesis by hepatic peroxisome proliferators: Evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans. Crit. Rev. Toxicol. 12, 1-58.
144. Reddy, J. K., Lalwani, N. D., Qureshi, S. A., Reddy, M. K., and Moehle, C. M. (1984). Induction of hepatic peroxisome proliferation in non-rodent species, including primates. Am. J. Pathol. 114, 171-183.
145. Reddy, J. K., Azarnoff, D. L., and Sell, S. (1979). Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferation, (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid (WY-14,643), in rat and mouse liver. Cancer Res. 39, 152-161.
146. Rhodes, C., Orton, T. C., Pratt, I. S., et. al. (1986). Comparative pharmacokinetics and subacute toxicity of di(2-ethylhexyl)phthalate (DEHP) in rats and marmosets: Extrapolation of effects in rodents to man. Environ. Health Perspect. 65, 299-308.
147. Richert, L., Price, S., Chesne, C., Maita, K., and Carmichael, N. (1996). Comparison of the induction of hepatic peroxisome proliferation by herbicide oxadiazon in vivo in rats, mice, and dogs and in vitro in rat and human hepatocytes. Toxicol. Appl. Pharmacol. 141, 35-43.
148. Roberts, R. A. (1996). Non-genotoxic hepatocarcinogenesis: Suppression of apoptosis by peroxisome proliferators. Ann. N.Y. Acad. Sci. 804, 588-611.
149. Rock, G., Secours, V. E., Franklin, C. A., Chu, I., and Villeneuve, D. C. (1978). The accumulation of mono-2-ethylhexylphthalate (MEHP) during storage of whole blood and plasma. Transfusion 18, 553-558.
150. Rodricks, J. V., and Turnbull, D. (1987). Interspecies differences in peroxisomes and peroxisome proliferation. Toxicol. Ind. Health 3, 197-212.
151. Rose, M. L., Germolec, D. R., Schoonhoven, R., and Thurman, R. G. (1997). Kupffer cells are causally responsible for the mitogenic effect of peroxisome proliferators. Carcinogenesis 18, 1453-1456.
152. Rusyn, I., Tsukamoto, H., and Thurman, R. G. (1998) WY-14-463 rapidly activates nuclear factor FB in Kupffer cells before hepatocytes. Carcinogenesis 19, 1217-1222.
153. 6-ethenoadenine (e-A). NATO Conference on DNA damage and repair, Nov. 1997.
154. Rubin, R. J., and Schiffer, C. A. (1976). Fate in humans of the plasticizer, di-2-ethylhexyl phthalate, arising from transfusion of platelets stored in vinyl plastic bags. Transfusion 16(4), 330-335.
155. Sakuma, M., Yamada, J., and Suga, T. (1992). Comparison of the inducing effect of dehydroepiandrosterone on hepatic peroxisome proliferation-associated enzymes in several rodent species. A short-term administration study. Biochem. Pharmacol. 43, 1269 -1273.
156. Sausen, P. J., Lee, D. C., Rose, M. L., and Cattley, R. C. (1995). Elevated 8-hydroxydeoxy-guanosine in hepatic DNA of rats following exposure to peroxisome proliferators: Relationship to mitochondrial alterations. Carcinogenesis 16, 1795-1801.
157. Short, R. D., Robinson, E. C., Lington, A. W., and Chin, A. E. (1987). Metabolic and peroxisome proliferation studies with di(2-ethylhexyl)phthalate in rats and monkeys. Toxicol. Ind. Health 3, 185-195.
158. Sjöberg, P., Bondesson, U., and Hammarlund, M. (1985). Non-linearities in the pharmacokinetics of di-(2-ethylhexyl) phthalate and metabolites in male rats. Arch. Toxicol. 58, 72-77.
159. Small, G. M., Burdett, K., and Connock, N. V. (1982). Clofibrate-induced changes in enzyme activities in liver, kidneys and small intestine of male mice. Ann. N.Y. Acad. Sci. 386, 460-463.
160. Smith, L. L., and Elcombe, C. R. (1989). Mechanistic studies: Their role in the toxicological evaluation of pesticides. Food Addit. Contam. 6(Suppl. 1), S57-S65.
161. Stott, W. T. (1988). Chemically induced proliferation of peroxisomes. Regul. Toxicol. Pharmacol. 8, 125-129.
162. Takagi, A., Sai, K., Umemura, T., Hasegawa, R., and Kurokawa, Y. (1990a). Significant increase of 8-hydroxydeoxyguanosine in liver DNA of rats following short-term exposure to the peroxisome proliferators di(2-ethylhexyl)phthalate and di(2-ethylhexyl)adipate. Jpn. J. Cancer Res. (Gann) 81, 213-215.
163. Takagi, A., Sai, K., Umemura, T., Hasegawa, R., and Kurokawa, Y. (1990b). Relationship between hepatic peroxisome proliferation and 8-hydroxydeoxyguanosine formation in liver DNA of rats following long-term exposure to three peroxisome proliferators: di(2ethylhexyl) phthalate, aluminum clofibrate and simfibrate. Cancer Lett. 53, 33-38.
164. Tamura, H., Iida, T., Watanabe, T., and Suga, T. (1991). Lack of induction of hepatic DNA-damage on long-term administration of peroxisome proliferators in male F-344 rats. Toxicology 69, 55-62.
165. Tanaka, A., Adachi, T., Takahashi, T., and Yamaha, T. (1975). Biochemical studies on phthalic esters. I. Elimination, distribution and metabolism of di-(2-ethylhexyl)phthalate in rats. Toxicology 4, 253-264.
166. Tobe, M., Suzuki, Y., Ikeda, Y., and Naito, K. (1984). A Study on Toxicity of Phthalates and Adipate. Chronic Toxicity Test in Mice, FDA FAP No. IT 3573: 010623-010676.
167. Tomaszewski, K. E., Derks, M. C., and Melnick, R. L. (1987). Acyl CoA oxidase is the most suitable marker for hepatic peroxisomal changes caused by treatment of F344 rats with di(2-ethylhexyl)-phthalate. Toxicol. Lett. 37, 203-212.
168. Tucker, M. J., Topham, J. C., and Marsden, A. M. (1988). Long term effects of clofibrate treatment in the primate (Callithrix Jacchus). Toxicologist 8(1), Abstract 435.
169. Tucker, M. J., and Orton, T. C. (1993). Toxicological studies in primates with three fibrates. In Peroxisomes: Biology and Importance in Toxicology and Medicine (G. Gibson and B. Lake, Eds.), pp. 425-447. Taylor and Francis, London.
170. Tucker, M. J., and Orton, T. C. (1995). Comparative Toxicology of Hypolipidaemic Fibrates. Taylor and Francis, London.
171. Tugwood, J. D., Aldridge, T. C., Lambe, K. G., McDonald, N., and Woodyatt, N. J. (1996). Peroxisome proliferator-activated receptors: Structures and functions. Ann. N.Y. Acad. Sci. 804, 252-265.
172. Tugwood, J. D., Holden, P. R., James, N. H., Prince, R. A., and Roberts, R. A. (1998). Isolation and characterization of a functional peroxisome proliferator-activated receptor-alpha from guinea pig. Arch. Toxicol. 72, 169-177.
173. Ward, J. M., Rice, J. M., Creasia, D., et al. (1983). Dissimilar patterns of promotion by di-(2-ethylhexyl)phthalate and phenobarbital of hepatocellular neoplasia initiated by diethylnitrosamine in B6C3F1 mice. Carcinogenesis 4, 1021-1029.
174. Ward, J. N., Peters, J. M., Perella, C. M., and Gonzalez, F. J. (1998). Receptor and nonreceptor-mediated organ-specific toxicity of di(2-ethylhexyl)phthalate (DEHP) in peroxisome proliferator-activated receptor a-null mice. Toxicol. Pathol. 26, 240-246.
175. Watanabe, T., Horie, S., Yamada, J., Isaji, M., Nishigaki, T., Naito, J., and Suga, T. (1989). Species differences in the effects of beza-fibrate, a hypolipidemic agent, on hepatic peroxisome-associated enzymes. Biochem. Pharmacol. 38, 367-371.
176. Williams, G. M. (1992). DNA reactive and epigenetic carcinogens. Exp. Toxicol. Pathol. 44, 457-464.
177. Williams, G. M., Maruyama, H., and Tanaka, T. (1987). Lack of rapid initiating, promoting or sequential syncarcinogenic effects of di(2-ethylhexyl)phthalate in rat liver carcinogenesis. Carcinogenesis 8, 875-880.
178. Williams, G. M., and Perrone, C. (1996). Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens. Ann. N.Y. Acad. Sci. 804, 554-572.
179. Zhu, Y., Qi, C., Jain, S., Rao, M. S., and Reddy, J. K. (1997). Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor-alpha. J. Biol. Chem. 272, 25500-25506.